Clinical trial · Interventional
Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events
NCT02733965CI-TRIAL-00021705PharmaOncounknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The improvement of the care pathway of oncology patients through Clinical Pharmacy activities for outpatients (such as pharmaceutical consultation) should be implemented and evaluated. In order to improve the care pathway of patients on anticancer oral therapies, The investigators suggest in this research project to integrate into the medical care a "Clinical Pharmacy follow-up" for the patient at the hospital in the form of "pharmaceutical consultations". These pharmaceutical consultations carried out in coordination with the hospital clinical teams also aim to make the link between the hospital and community pharmacists.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oral Anticancer Therapy. | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Pharmaceutical Consultations | Other | — | UNRESOLVED |
| Pharmaceutical Consultations | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- standard course
- description
- The patients in the control group will have a "classic" course of treatment. They will receive -An educational assessment consisting on evaluating the patient's educational needs. * Group workshops entitled "Disease and drugs", "Dietary and sports activity", "Psychology Workshop" during which the patient will be able to participate in order to get all the information he needs. * Individual therapeutic education sessions to specifically and personally highlight certain non-pharmaceutical educational needs identified at the time of the educational assessment. Moreover, in the control arm, a systematic "short pharmaceutical interview" with an average duration of 15 minutes will be proposed to patients at the initiation of treatment, at D15 after the prescription (considered as the date of inclusion) at M1 and then every 3 months (M3, M6, M9 and M12):
- interventionNames
- Other: No Pharmaceutical Consultations
- type
- OTHER
- label
- Long Pharmaceutical Consultations
- description
- The patients will receive the same course of treatment as in the control group, including the D0 short pharmaceutical interview, with the same prerogatives of acceptance or rejection of participation in the TPE program. Short pharmaceutical interviews from D15 to M12 will be replaced by long pharmaceutical consultations of 30 to 60 minutes. The latter consisting in a full clinical medication review and incorporating the pedagogic aspects addressed in the short pharmaceutical interviews but for all therapeutic drugs taken by the patient. Additional consultations are possible on the request of the oncologist and/or patient. The consultations carried out at the request of the oncologist and/or the patient will be counted The first part of the pharmaceutical consultation focuses on a complete clinical medication review including Establishment of the patient profile: medical history, drug allergies and intolerance, comorbidities, age, understanding capacities, organizational capacity
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients over 18 years of both sexes * Patients with cancer pathology whatever stage/grade and associated comorbidities he has * Patients treated with oral cancer therapy for less than a month regardless of the therapy line * Have accepted to participate and signed the non-opposition form Exclusion Criteria: * Patients less than 18 years of age and all vulnerable people, in accordance with French laws (pregnant women, adults under guardianship or trusteeship; persons deprived of liberty) * Patients under treatment for more than one month * Patients refusing to participate in the research project
References
Publications (0)
Data not yet available
No reference posted for this study.